- Home
- CLST vs UNCY Comparison
CLST vs UNCY Comparison
Compare CLST & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLST
- UNCY
- Stock Information
- Founded
- CLST 1922
- UNCY 2016
- Country
- CLST United States
- UNCY United States
- Employees
- CLST N/A
- UNCY N/A
- Industry
- CLST
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CLST
- UNCY Health Care
- Exchange
- CLST Nasdaq
- UNCY Nasdaq
- Market Cap
- CLST 51.8M
- UNCY 56.4M
- IPO Year
- CLST N/A
- UNCY 2021
- Fundamental
- Price
- CLST $12.55
- UNCY $4.41
- Analyst Decision
- CLST
- UNCY Strong Buy
- Analyst Count
- CLST 0
- UNCY 4
- Target Price
- CLST N/A
- UNCY $63.75
- AVG Volume (30 Days)
- CLST 2.2K
- UNCY 371.3K
- Earning Date
- CLST 07-24-2025
- UNCY 08-26-2025
- Dividend Yield
- CLST N/A
- UNCY N/A
- EPS Growth
- CLST N/A
- UNCY N/A
- EPS
- CLST 0.58
- UNCY N/A
- Revenue
- CLST $11,354,000.00
- UNCY N/A
- Revenue This Year
- CLST N/A
- UNCY N/A
- Revenue Next Year
- CLST N/A
- UNCY $1,178.98
- P/E Ratio
- CLST $21.68
- UNCY N/A
- Revenue Growth
- CLST 164.54
- UNCY N/A
- 52 Week Low
- CLST $10.67
- UNCY $2.02
- 52 Week High
- CLST $14.23
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- CLST 57.28
- UNCY 45.66
- Support Level
- CLST $12.50
- UNCY $3.97
- Resistance Level
- CLST $12.59
- UNCY $4.43
- Average True Range (ATR)
- CLST 0.05
- UNCY 0.22
- MACD
- CLST 0.01
- UNCY 0.05
- Stochastic Oscillator
- CLST 73.06
- UNCY 45.36
About CLST Catalyst Bancorp Inc.
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.